CAR T-cell therapies have demonstrated efficacy in treating blood cancers but, so far, their safety and effectiveness in ...

Developing effective treatments and understanding how the mechanism of the immune system have always been challenging for ...

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...

Not everyone responds to statins, the standard treatment for people at risk of cardiovascular disease, so an alternative ...

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.

During a Case-Based Roundtable® event, Muhammad Umair Mushtaq, MD, discussed managing long-term toxicity concerns related to ...

This Review discusses the targets and mechanisms ... following the observation that bone-marrow-derived MSCs suppressed T-cell proliferation 16,17. These studies redirected the attention of ...

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Engineered immune cells called CAR-T cells are used in the treatment of cancer. Researchers from Uppsala University have now ...

Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying ...

Despite the powerful cancer-fighting capabilities of treatments based on CAR-T cells to fight a patient’s cancer, one key challenge is getting these treatments to more patients.